News‎ > ‎Full Stories‎ > ‎

8 August 2016

posted Aug 8, 2016, 7:16 AM by Beck Lockwood   [ updated Oct 14, 2016, 2:29 AM ]
Precision oncology symposium launched in Leeds

A new symposium discussing advances in precision oncology is being launched next week in Leeds.

Organised by the Leeds NIHR Diagnostic Evidence Co-operative and the new Leeds Centre for Personalised Medicine & Health, the symposium is expected to be an annual event, bringing together key stakeholders to discuss the translation and adoption of technological advances within the field of precision oncology.

The inaugural event, titled “Developing the pipeline toclinical adoption and impact”, will focus on the evolving precision oncology pipeline, increasingly welded together by partnerships between industry, academia and the NHS. It will take place on 19 October at the Queens Hotel in Leeds.

The programme will see key representatives from Innovate UK, NICE, the Academic Health Science Network, primary care and commissioning groups joined by academics and key industry stakeholders from across the UK and Canada.

Key areas of discussion will include building successful precision oncology-related industry – academic partnerships, the UK infrastructure for precision oncology development and delivery, and both the commissioning and adoption of new precision oncology technologies.

Novel methods for health-economic analyses of innovations in precision oncology will also be outlined, whilst representatives from the MRC Medical Bioinformatics Centre will summarise the growing role of health informatics in supporting both the development and evaluation of new precision oncology technologies.

Dr Chris Jones, Programme Coordinator and NIHR Academic Clinical Fellow in Clinical Oncology at the University of Leeds, says: “This promises to be a benchmark conference on a topic that many are calling for greater clarity on. This event is already attracting significant interest and we are looking forward to welcoming clinicians, academics and industry representatives to discuss how we can together drive advances in precision oncology in order to improve patient care”.

For more information email Dr Chris Jones at